With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

the FDA voluntarily agreed to reconsider whether there is still a tirzepatide shortage and will allow those large-scale compounding pharmacies to continue producing copies of the drug for now ...

drug tirzepatide (Eli Lilly and Company). Meanwhile, Novo Nordisk, which makes semaglutide, has asked the FDA to add the GLP-1 to a list of drugs too difficult to compound. This would essentially ...

Compounded GLP-1s ... liraglutide, and tirzepatide — and other GLP-1s — is out of reach for most people. Plus, you may need to take the drug for a long time for weight management or diabetes ...